HAVCR1 and hydrops fetalis: Several authors have even raised the possibility of dosing syndecan-1 in patients with HF and AKI instead of the well-established kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (N-GAL).